Mineralys Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MLYS and other ETFs, options, and stocks.About MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease.
CEOJon Congleton
CEOJon Congleton
Employees51
Employees51
HeadquartersRadnor, Pennsylvania
HeadquartersRadnor, Pennsylvania
Founded2019
Founded2019
Employees51
Employees51
MLYS Key Statistics
Market cap1.03B
Market cap1.03B
Price-Earnings ratio-4.34
Price-Earnings ratio-4.34
Dividend yield—
Dividend yield—
Average volume1.00M
Average volume1.00M
High today$15.55
High today$15.55
Low today$14.94
Low today$14.94
Open price$15.22
Open price$15.22
Volume862.10K
Volume862.10K
52 Week high$18.38
52 Week high$18.38
52 Week low$8.24
52 Week low$8.24
Analyst ratings
88%
of 8 ratingsBuy
87.5%
Hold
12.5%
Sell
0%
People also own
Based on the portfolios of people who own MLYS. This list is generated using Robinhood data, and it’s not a recommendation.